GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
183
c/glp1eu·posted 1 year ago by u/pavel_kimani

[Question] how do you actually verify prescription

Question

how do you actually verify prescription. I am not trying to be the "source?" guy. I would just like a source.

Pharmacy margins and dispensing fees are regulated nationally, which explains price differences that otherwise look arbitrary.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Supply notices are issued nationally. A notice in one member state does not imply availability problems in another, even for the same product.

Sceptical readings welcome. The confident ones are the ones I distrust.

189 up / 6 down97% upvoted24 commentsid 1wck1027 Dec 2024

24 comments

18 in this archive, depth 4

best — the order this archive was captured in

u/mei_cardoso48 points·1 year ago

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences. Those are decided by different bodies with different processes.

replysharereportpermalink
u/amara_haddad39 points·1 year ago

Marketing authorisation is granted centrally for these products; reimbursement, pricing and prescribing criteria are national competences.

mei_cardoso is right about cross-border recognition being narrower than the summaries suggest.

replysharereportpermalink
u/noor_ivaturi-17 points·1 year ago

Which member state?

replysharereportpermalink
u/still_here_20261 point·1 year ago

reimbursement is national, not European, and that is the whole board

replysharereportpermalink
load more comments (5) →
u/cardio_endpoint_c28 points·1 year ago

The structure that makes this board make sense, once.

Marketing authorisation for these products is granted centrally, which is why the same product exists across the union. Everything after that — whether it is reimbursed, on what criteria, at what price, in what pack size, dispensed under what margin rules — is decided nationally.

So "is it covered" has twenty-seven answers, "what does it cost" has twenty-seven answers plus within-country variation, and only "is it authorised" has one. Almost every argument on this board is two people answering different questions from different countries, both correctly.

replysharereportpermalink
u/eu_apotheke_a9 points·1 year ago

Yes — keep both the prescription and the receipt. Claims processes ask for both and never at a convenient moment.

replysharereportpermalink
u/wanjiru_ramos22 points·1 year ago

the EMA authorises, member states decide who pays

replysharereportpermalink
u/cato_batista17 points·1 year ago

EU-wide advice is almost always wrong somewhere

replysharereportpermalink
u/milan_mensah5 points·1 year ago

Cosigning on cross-border prescriptions. The rules exist and they are narrower than the summaries suggest.

replysharereportpermalink
u/pavel_kimaniOP2 points·1 year ago

The variation between pharmacies inside my own country was larger than the variation I had been chasing across the border.

replysharereportpermalink
load more comments (3) →
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/glp1eu

European access, country by country: prescription routes, reimbursement reality, pharmacy stock, EMA notices and the fact that "EU rules" is usually a national question wearing a European hat.

32kmembers
62submissions
Apr 2024created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
c/glp1eu rules
  1. Tag your country in the title. Bare "EU" questions get a template reply.
  2. Pricing posts need the date and the currency.
  3. EMA and national agency claims need a citation.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.